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Abstract
Background: The goal of the present study was to assess the effect of genetic variability at the
APOA5/A4/C3/A1 cluster locus on the risk of metabolic syndrome.
Methods: The APOA5 Ser19Trp, APOA5 -12,238T>C, APOA4 Thr347Ser, APOC3 -482C>T and
APOC3 3238C>G (SstI) polymorphisms were analyzed in a representative population sample of
3138 men and women from France, including 932 individuals with metabolic syndrome and 2206
without metabolic syndrome, as defined by the NCEP criteria.
Results: Compared with homozygotes for the common allele, the odds ratio (OR) [95% CI] for
metabolic syndrome was 1.30 [1.03–1.66] (p = 0.03) for APOA5 Trp19 carriers, 0.81 [0.69–0.95] (p
= 0.01) for APOA5 -12,238C carriers and 0.84 [0.70–0.99] (p = 0.04) for APOA4 Ser347 carriers.
Adjustment for plasma triglycerides, (but not for waist girth, HDL, blood pressure or glycemia –
the other components of metabolic syndrome) abolished these associations and suggests that
triglyceride levels explain the association with metabolic syndrome. There was no association
between the APOC3 -482C>T or APOC3 3238C>G polymorphisms and metabolic syndrome. The
decreased risk of metabolic syndrome observed in APOA5 -12,238C and APOA4 Ser347 carriers
merely reflected the fact that the APOA5 Trp19 allele was in negative linkage disequilibrium with
the common alleles of APOA5 -12,238T>C and APOA4 Thr347Ser polymorphisms.
Conclusion: The APOA5 Trp19 allele increased susceptibility to metabolic syndrome via its impact
on plasma triglyceride levels.
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Background
Metabolic syndrome is a complex disease characterized by
the ustering of several metabolic disorders [1,2]. Excess
body weight, insulin resistance, altered plasma lipid levels
& glucose homeostasis and increased blood pressure are
the principal components of this cluster. Environmental
influences (such as low physical activity and an inappro-
priate diet) play a major role in the development of met-
abolic syndrome. Furthermore, familial aggregation of
metabolic disorders has been reported and suggests a
genetic contribution to the etiology of this syndrome [3-
5]. Accordingly, it has been reported that genetic variabil-
ity at several loci is associated with an increased risk of
metabolic syndrome [6-12].
The APOA5 gene is located on chromosome 11q23 and
codes for a 369 amino-acid protein secreted by the liver
[13]. In the plasma, APOA5 is bound to triglyceride-rich
and high-density lipoproteins. APOA5 reduces plasma
triglyceride levels by inhibiting VLDL-triglyceride produc-
tion and stimulating LPL-mediated triglyceride hydrolysis
[14-18]. In vitro, insulin decreases APOA5 promoter activ-
ity – suggesting that the hormone may affect triglyceride
levels via an interaction with APOA5 [19]. Given its role
in triglyceride metabolism and its interaction with insu-
lin, the APOA5 gene is a candidate gene for metabolic syn-
drome.
Several common single nucleotide polymorphisms
(SNPs) have been described in the APOA5 gene locus;
these include a T>C substitution at -12,238 (SNP4), a T>C
substitution at -1131 (SNP3; rs662799) and a C>G muta-
tion at the first base of codon 19 (rs3135506; c.56C>G)
that changes a serine (Ser) residue into a tryptophan (Trp)
[20]. An association between the APOA5 Ser19Trp poly-
morphism and plasma triglycerides has been reported in
several population samples [13,20-23]. In contrast, an
association between the APOA5  -12,238T>C polymor-
phism and plasma lipid variables has not been consist-
ently observed. Together with APOA4,  APOC3  and
APOA1, the APOA5 gene lies within an expanded gene
cluster [13,24]. Strong linkage disequilibrium (LD) has
been detected for SNPs in this cluster [24]. The APOA5
Ser19Trp and APOC3  3238C>G SNPs (Sst1; rs5128;
c.386C>G) both tag common haplotypes in this cluster –
haplotypes that may have independent effects on plasma
triglycerides.
The goal of the present study was to assess the relative con-
tribution of SNPs in the APOA5/A4/C3/A1 locus to the
risk of metabolic syndrome by analyzing a limited
number of representative SNPs within the cluster and a
large population-based sample from 3 areas of France.
Methods
Subjects
Participants were recruited as part of the WHO-MONICA
population survey conducted from 1995 to 1997 in three
different parts of France: the Lille Urban Community in
northern France (n = 1168), the Bas-Rhin county in east-
ern France (n = 1117) and the Haute-Garonne county in
southern France (n = 1176). The protocol was approved
by the appropriate independent ethics committee in each
center. Subjects (aged 35–64) were randomly selected
from electoral rolls after stratification by town size, gender
and age in order to obtain 200 participants for each gen-
der and each 10-year age group (WHO-MONICA Project
protocol) [25]. A total of 1746 men and 1715 women
completed the recruitment procedure. Subsequently, 323
subjects were excluded due to missing data on at least one
criterion for metabolic syndrome.
After providing written informed consent, participants
filled out a standard questionnaire and physical measure-
ments were taken by a specially trained nurse. The ques-
tionnaire covered questions on socioeconomic factors,
physical activity, alcohol consumption, smoking status,
personal & family medical history and current medica-
tions taken (if any). The level of leisure-time physical
activity during was categorized as follows: none, light
(light physical activity almost every week), intense (at
least 20 minutes of intense physical activity more than
once a week). In terms of smoking exposure, subjects were
categorized as never-smokers, former smokers and current
smokers (i.e. subjects reporting at least one cigarette per
day). Total alcohol intake was expressed as the sum of ml
alcohol per week from wine, beer, cider and spirits. Alco-
hol consumption was categorized in 4 Q1-Q4 classes for
men [≤100 ml/week; 100–250 ml/week; 250–500 ml/
week; >500 ml/week] and for women [0 ml/week; 0–60
ml/week; 60–190 ml/week; > 190 ml/week]. Educational
level was assessed by counting the number of years of
schooling and classifying the values into 3 categories: pri-
mary, secondary/technical and university. Anthropomet-
ric measurements included body weight (rounded to the
nearest even decimal), waist girth (at a level midway
between the lower rib margin and the iliac crest, to the
nearest 0.5 cm) and were performed on subjects in light
clothing without shoes. Body mass index was calculated
according to the Quetelet equation.
Diabetic subjects were identified by fasting glycemia ≥126
mg/dl or antidiabetic treatment. Abdominal obesity was
defined by waist girth ≥102 cm in men and ≥88 cm in
women. Metabolic syndrome was defined (according to
the NCEP III recommendations [26]) by the presence of at
least 3 or more of the following abnormalities: waist girthBMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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≥102 cm in men and ≥88 cm in women, triglycerides ≥ 1.7
mmol/L or treatment with fibrates, HDL-cholesterol
<1.04 mmol/L in men and <1.29 mol/L in women, blood
pressure ≥ 130/85 mm Hg or treatment with blood pres-
sure-lowering medications and fasting glucose ≥ 6.1
mmol/L or type 2 diabetes. Additional analyses were per-
formed using the International Diabetes Federation (IDF)
definition [27] of metabolic syndrome. This definition is
based on the same criteria as the NCEP definition except
that (i) increased waist girth is a mandatory criteria and
(ii) the waist cut-offs are 94 and 80 cm for European men
and women, respectively.
Laboratory methods
A 20 mL blood sample was drawn into a disodium EDTA
tube (after the subjects had fasted for at least 10 hours),
stored at room temperature and centrifuged within 4
hours. All measurements were performed in a central lab-
oratory (Purpan Hospital, Toulouse, France). Cholesterol
and triglyceride levels were measured using enzyme assays
(Boehringer Mannheim, Mannheim, Germany). High
density lipoprotein (HDL) cholesterol was measured after
sodium phosphotungstate/magnesium chloride precipi-
tation (Boehringer Mannheim, Mannheim, Germany).
Glucose was measured using the standard glucose hexoki-
nase method (DuPont Dimension, Brussels, Belgium).
The APOA5 Ser19Trp polymorphism was assessed in an
Amplifluor®  genotyping system using the following
probes: APOA5-F1: 5' GAAGGTGACCAAGTTCATGCTTC-
CCTCTCCACAGCGTTTTC-3'; APOA5-F2: 5'-
GAAGGTCGGAGTCAACGGATTTCCCTCTCCACAGCGT
TTTG-3' and APOA5-R: 5'-TGAAGTAGTCCCA-
GAAGCCTTT-3'. In the sample, 1.6% was undetermined.
Likewise, the APOC3 3238C>G (SstI) polymorphism was
assessed using the following probes: APOC3-F1: 5'-
GAAGGTCGGAGTCAACGGATTACCTGCCTATCCATC-
CTGCC-3', APOC3-F2: 5'-GAAGGTGACCAAGTTCAT-
GCTACCTGCCTATCCATCCTGCG-3' and APOC3-R: 5'-
GCACTGAGAATACTGTCCCTTT-3'. In the sample, 3.5%
was undetermined. The APOC3  -482C>T (rs2854117)
polymorphism was also assessed in an Amplifluor® system
using the following probes: APOC3-F1: 5'-
GAAGGTGACCAAGTTCATGCTAGTAAAGGCACAGAA-
GACCG-3', APOC3-F2: 5'-GAAGGTCGGAGTCAACG-
GATTGAGTAAAGGCACAGAAGACCA-3' and APOC3-R:
5'-TGAAACCCAGAGATGGAGGT-3'. In the sample, 3.8%
was undetermined. The APOA4 Thr347Ser polymorphism
was assessed as previously described [28]. The APOA5 -
12,238T>C polymorphism was genotyped with an RFLP-
based method using the following primers: forward 5'-
GTGCCTGTCACCACCGTTTG-3' and reverse 5'-
ATGCATTAGCCTCTGCTGTTC-3' (generating a forced
restriction site for HaeIII). The 162 bp PCR fragment was
cut by HaeIII into 2 fragments (141 and 21 bp) for the T
allele, whereas a single uncut product resulted for the C
allele. Products were resolved on 3% agarose gels. For
each method, around 10% of the samples were genotyped
twice and no discordant genotypes were observed.
Statistical analyses
General linear models (GLM) and chi-square tests were
used to compare the clinical and biological characteristics
of subjects with or without metabolic syndrome. Further-
more, GLM and Chi-square tests were used to compare
centers in terms of mean values and the distributions of
variables and genotypes, respectively. A GLM adjusted for
age, gender and center was used to compare genotype
groups in terms of metabolic syndrome criteria. Subjects
receiving a treatment that may have affected the level of
the variable were excluded from these analyses. Chi-
square tests and logistic regression analyses were used to
test the association between the various genotypes and
metabolic syndrome. For logistic regression analyses, car-
riers of at least one minor allele were compared with sub-
jects who were homozygous for the frequent allele
(dominant model), while adjusting for age, gender and
center. The threshold for statistical significance was set to
5%. Linkage disequilibrium between loci was tested using
a log-likelihood-ratio test [29]. Disequilibrium was
expressed in terms of normalized difference D' = D/Dmax
or D/Dmin [30]. Haplotype frequencies were estimated
using a stochastic version of the expectation-maximiza-
tion algorithm, as implemented in Thesias software
[31,32]. Differences in haplotype frequencies when com-
paring groups of subjects with or without metabolic syn-
drome were examined using a log-likelihood ratio statistic
test, which was computed from the haplotype frequency
log-likelihoods for each of the two groups estimated in
Thesias.
Results
Table 1 shows the biological and clinical characteristics of
the subjects with (n = 932) and without (n = 2206) meta-
bolic syndrome as defined by NCEP III. As expected, body
mass index, waist girth, triglyceridemia, cholesterolemia,
glycemia, systolic and diastolic blood pressure were
higher and HDL-cholesterol levels were lower in subjects
with metabolic syndrome than in subjects without meta-
bolic syndrome (all p < 0.0001). Subjects with metabolic
syndrome were less physically active and had spent less
time in education than those without metabolic syn-
drome. The proportion of smokers was lower in the met-
abolic syndrome group.
The  APOA5  Ser19Trp,APOA5  -12,238T>C,  APOA4
Thr347Ser, APOC3 -482C>T and APOC3 3238C>G geno-
types did not deviate from Hardy-Weinberg equilibrium.
Table 2 shows the linkage disequilibrium matrix in sub-
jects without metabolic syndrome. Overall, the |D'| varied
from 0.29 to 1. The APOA5 and APOA4 SNPs were in theBMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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same haplotype block (|D'|≥0.85); however, due to differ-
ences in minor allele frequencies, the r2  values were
almost nil. Within this block, both APOA5 -12,238T>C
and APOA4 Thr347Ser SNPs were in negative disequilib-
rium with the APOA5 Ser19Trp SNP. Both APOC3 SNPs
were within the same linkage disequilibrium block (D' =
0.91). Lastly, the APOA4 Thr347Ser SNP was in negative
linkage disequilibrium with the APOC3 3238C>G SNP
(D' = -0.92) and thus showed some overlap with the
APOC3 haplotype block.
Table 3 shows the metabolic syndrome-related anthropo-
metric, biological and clinical parameters in subjects with-
out metabolic syndrome and as a function of the 5
polymorphisms. Multivariate analyses (adjusted for age,
gender and center) revealed that mean triglyceride levels
were significantly higher in APOA5 Trp19 (p < 0.0001; p
Table 1: Anthropometric, clinical and biological characteristics of subjects with or without metabolic syndrome
Without metabolic syndrome With metabolic syndrome p
n2 2 0 6 9 3 2
age (y) 49.4 ± 8.4 54.2 ± 8.1 <0.0001
men 1044 (47.3) 553 (59.3) <0.0001
BMI (kg/m2) 24.8 ± 3.6 29.9 ± 4.7 <0.0001
Waist (cm) 85.3 ± 11.3 101.5 ± 11.6 <0.0001
Cholesterol (mmol/l) 5.8 ± 1.0 6.1 ± 1.1 <0.0001
Triglycerides (mmol/l) 1.00 ± 0.52 2.20 ± 2.32 <0.0001
HDL (mmol/l) 1.58 ± 0.43 1.19 ± 0.34 <0.0001
Glucose (mmol/l) 5.20 ± 0.76 5.95 ± 1.30 <0.0001
Diabetes (%) 2.4 19.5 <0.0001
SBP (mm Hg) 125.7 ± 15.8 140.6 ± 16.9 <0.0001
DBP (mm Hg) 79.0 ± 10.1 87.9 ± 11.2 <0.0001
Smoking 0.032
never 1069 (48.5) 432 (46.4)
former 629 (28.5) 308 (33.0)
current 508 (23.0) 192 (20.6)
Physical activity <0.0001
none 449 (20.4) 244 (26.3)
light 1058 (48.0) 490 (52.7)
intense 697(31.6) 195 (21.0)
Alcohol intake 0.0013
Q1 760 (34.5) 303 (32.5)
Q2 574 (26.0) 201 (21.6)
Q3 535 (24.3) 241 (25.9)
Q4 337 (15.2) 187 (20.0)
Educational level <0.0001
low 433 (19.6) 312 (33.5)
intermediate 952 (43.2) 410 (44.0)
high 821 (37.2) 210 (22.5)
Values are means± SD or n (%).
BMI : body mass index ; HDL : high density lipoprotein ; SBP/DBP : systolic and diastolic blood pressure ; alcohol intake is in quartiles.
Table 2: D' and r2 values for linkage disequilibrium among polymorphisms in subjects without metabolic syndrome
APOA5 Ser19Trp APOA5 -12,238 T>C APOA4 Thr347Ser APOC3 -482 C>T APOC3 3238 C>G
APOA5 Ser19Trp - -0.85 -1 -0.73 -0.41
APOA5 -12,238 T>C 0.02 - 0.95 0.29 -0.58
APOA4 Thr347Ser 0.02 0.40 - 0.45 -0.92
APOC3 -482 C>T 0.01 0.06 0.13 - 0.91
APOC3 3238 C>G 0.00 0.02 0.02 0.23 -
D' upper right corner ; r2 lower left cornerBMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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< 0.0001 in a dominant model),APOC3 -482T (p = 0.04
in a dominant model) and APOC3 3238G (p < 0.0001; p
< 0.0001 in a dominant model) allele carriers. Conversely,
mean triglycerides were lower in APOA5 -12,238C (p <
0.01; p = 0.003 in a dominant model), APOA4 Ser347 (p
= 0.04 in a dominant model) allele carriers than in non-
carriers. The mean HDL-cholesterol value was signifi-
cantly higher in APOA5 -12,238C (p = 0.04; p = 0.02 in a
dominant model) allele carriers than in non-carriers.
Systolic and diastolic blood pressures were higher in
APOA5 Trp19 carriers (p = 0.03 in a dominant model)
and systolic blood pressure was lower in APOA4 Ser347
carriers (p = 0.03 in a dominant model). There were no
other statistically significant associations for any of the
SNPs. Further adjustment for physical activity, alcohol
consumption, smoking habits and educational level
yielded similar results (data not shown). These associa-
tions were similarly observed in all three centers (i.e. there
was no significant interaction with geographical area).
In order to assess the contribution of the genetic variabil-
ity to plasma triglyceride levels, haplotype analyses were
performed in subjects without metabolic syndrome using
the 5 SNPs in the following order: APOA5
(Ser(C)19Trp(G), -12,238T>C),APOA4  (Thr(A)347Ser
(T)) and APOC3 (-482C>T, 3238C>G). Eight haplotypes
Table 3: Mean levels of metabolic syndrome-related anthropometric, biological and clinical parameters in subjects without metabolic 
syndrome according to the 5 polymorphisms
APOA5 Ser19Trp Ser19Ser Ser19Trp Trp19Trp pp a pb
Waist (cm) 85 ± 11 84 ± 11 81 ± 8 0.49 0.23 0.77
TG (mmol/l) d 1.26 ± 1.1 1.59 ± 2.4 2.46 ± 2.3 <0.0001 c <0.0001 c 0.07 c
HDL (mmol/l) d 1.48 ± 0.4 1.49 ± 0.5 1.2 ± 0.5 0.56 0.78 0.59
Glucose (mmol/l) e 5.4 ± 1 5.4 ± 0.8 5.5 ± 0.4 0.72 0.43 0.83
SBP (mm Hg) f 129 ± 17 131 ± 18 135 ± 13 0.081 0.03 0.47
DBP (mm Hg) f 81 ± 11 82 ± 10 84 ± 10 0.082 0.03 0.39
APOA5 -12,238 T>C TT TC CC
Waist (cm) 85 ± 11 85 ± 11 85 ± 11 0.49 0.23 0.15
TG (mmol/l) d 1.31 ± 1.0 1.29 ± 1.4 1.32 ± 1.9 0.01 c 0.003 c 0.08 c
HDL (mmol/l) d 1.47 ± 0.4 1.49 ± 0.4 1.52 ± 0.5 0.04 0.02 0.10
Glucose (mmol/l) e 5.4 ± 1 5.4 ± 1.1 5.3 ± 0.8 0.31 0.52 0.15
SBP (mm Hg) f 129 ± 17 129 ± 18 129 ± 17 0.24 0.11 0.30
DBP (mm Hg) f 81 ± 11 81 ± 11 81 ± 10 0.79 0.54 0.49
APOA4 Thr347Ser Thr347Thr Thr347Ser Ser347Ser
Waist (cm) 85 ± 11 86 ± 11 86 ± 11 0.64 0.71 0.39
TG (mmol/l) d 1.31 ± 1 1.30 ± 1.8 1.22 ± 0.8 0.11 c 0.04 c 0.69 c
HDL (mmol/l) d 1.48 ± 0.4 1.49 ± 0.4 1.55 ± 0.5 0.24 0.24 0.09
Glucose (mmol/l) e 5.4 ± 1.1 5.4 ± 0.9 5.2 ± 0.7 0.44 0.63 0.20
SBP (mm Hg) f 130 ± 18 129 ± 17 127 ± 16 0.09 0.03 0.82
DBP (mm Hg) f 81 ± 11 81 ± 11 81 ± 10 0.92 0.83 0.84
APOC3 -482 C>T CC CT TT
Waist (cm) 85 ± 11 85 ± 11 85 ± 11 0.75 0.78 0.49
TG (mmol/l) d 1.27 ± 1 1.34 ± 1 1.33 ± 1 0.09 c 0.04 c 0.07 c
HDL (mmol/l) d 1.47 ± 0.4 1.49 ± 0.4 1.51 ± 0.4 0.68 0.54 0.66
Glucose (mmol/l) e 5.4 ± 1 5.4 ± 1 5.4 ± 0.8 0.93 0.78 0.87
SBP (mm Hg) f 129 ± 17 129 ± 18 128 ± 17 0.47 0.45 0.28
DBP (mm Hg) f 81 ± 10 81 ± 11 81 ± 11 0.93 0.72 0.85
APOC3 3238 C>G CC CG GG
Waist (cm) 85 ± 11 86 ± 11 84 ± 15 0.25 0.1 0.66
TG (mmol/l) d 1.27 ± 1.4 1.44 ± 1.2 1.56 ± 1.2 <0.0001 c <0.0001 c 0.05 c
HDL (mmol/l) d 1.49 ± 0.4 1.47 ± 0.4 1.43 ± 0.4 0.15 0.6 0.29
Glucose (mmol/l) e 5.4 ± 1 5.4 ± 0.8 5.5 ± 0.6 0.55 0.35 0.79
SBP (mm Hg) f 129 ± 17 129 ± 17 134 ± 21 0.19 0.52 0.28
DBP (mm Hg) f 81 ± 11 81 ± 11 84 ± 12 0.12 0.37 0.21
p values ajusted on age, gender and center ; pa and pb values for a dominant and recessive models, respectively; canalyses on log-transformed data ; 
BMI : body mass index ; TG : triglycerides ; HDL : high density lipoprotein ; SBP/DBP : systolic and diastolic blood pressure ; Exclusion of subjects 
treated : d with fibrates, e oral antidiabetic or insulin, f BP lowering therapy.BMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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had an estimated frequency of above 1% (accounting for
more than 97% of the existing haplotypes) and were used
in the analyses (Table 4). The overall association between
haplotypes and triglyceride levels was highly significant (p
< 4 × 10-8). By reference to the most common haplotype
(CTACC; estimated frequency: 0.45), two haplotypes were
significantly associated with raised plasma triglycerides.
The GTACC haplotype (estimated frequency: 0.05) that
carried the APOA5  Trp19 allele on the common back-
ground was associated with a 30% increase in triglyceride
levels (p < 10-6). The other haplotype (CTATG) carried
both the APOC3 -482T and 3238G minor alleles on the
common genetic background (estimated frequency: 0.08)
and was also associated with a 30% increase in triglyceride
levels (p < 10-6).
Table 5 shows the genotype distribution of the 5 SNPs in
subjects with or without metabolic syndrome. The two
groups of subjects differed in terms of the genotype distri-
bution of APOA5 -12,238T>C (p = 0.026) and APOA4
Thr347Ser (p = 0.034) SNPs. The adjusted odds ratio
(OR) and 95% confidence interval (CI) for metabolic syn-
drome in carriers of at least one minor allele (compared
with subjects homozygous for the frequent allele) are pre-
sented in Table 6. The APOA5 Trp19 allele conferred an
increased risk of metabolic syndrome (p = 0.03). In con-
trast, the APOA5  -12,238C (p = 0.01) and the APOA4
Ser347 (p = 0.04) alleles were associated with a lower risk
of metabolic syndrome. Adjustment for plasma triglycer-
ides but not for other metabolic syndrome criteria (i.e.
waist girth, HDL, glycemia and systolic blood pressure)
abolished these associations. Lastly, there was no signifi-
cant association between the APOC3  -482C>T and
3238C>G polymorphisms and metabolic syndrome.
Using the IDF criteria for metabolic syndrome, the ORs
[95%CI] for metabolic syndrome were similar in magni-
tude (data not shown).
Haplotype analyses using the 5 SNPs were performed to
assess the relationship with metabolic syndrome. The
overall association between the haplotypes and metabolic
syndrome was statistically significant (p = 0.011). With
respect to the most common haplotype (CTACC), 2 hap-
lotypes were significantly associated with metabolic syn-
drome. The GTACC haplotype (carrying the APOA5 Trp19
allele on the common background) was associated with a
33% greater risk of metabolic syndrome (p < 0.005). The
other haplotype (CCTTC, carrying the APOA5 12,238C,
the  APOA4  Ser347 and the APOC3  -482T alleles) was
associated with a 26% reduction in metabolic syndrome
risk (p = 0.03). Since the APOC3 and APOA5 SNPs are in
different haplotype blocks, the association with metabolic
syndrome was tested for the two blocks independently.
Using only the SNPs of APO5  (Ser19Trp, -12,238T>C)
and APOA4 Thr347Ser, we found 4 possible haplotypes
with a frequency of above 1%. When compared with the
common haplotype (CTA; estimated frequency: 0.58), the
GTA (estimated frequency 0.05) and the CCT (estimated
frequency 0.19) haplotypes were respectively associated
with a 33% greater risk (p < 0.02) and a 17% lower risk (p
= 0.034) of metabolic syndrome. Both associations disap-
peared after adjustment for triglyceride levels. In contrast,
Table 4: Haplotype frequencies and delta values of mean 
triglycerides in subjects without metabolic syndrome
Haplotype Frequency Δ TG p
CTACC 0.454 reference -
CCACC 0.130 0.037 0.13
CCTTC 0.118 0.003 0.93
CTATG 0.079 0.165 <10-6
CCTCC 0.075 -0.004 0.92
GTACC 0.050 0.165 <10-6
CTATC 0.043 -0.021 0.71
CCATC 0.022 -0.013 0.83
Only haplotypes with a frequency above 1% are represented. Order 
of the SNPS: APOA5 (Ser(C)19Trp(G), 12,238T>C), APOA4 
(Thr(A)347Ser(T)) and APOC3 (-482C>T, 3238C>G). p values 
adjusted for age, gender and center.
Table 5: Genotype distributions in subjects with or without 
metabolic syndrome (MS)
SNP p
APOA5 Ser19Trp Ser19Ser Ser19Trp Trp19Trp
Without MS 1960 (88.8) 241 (10.9) 5 (0.2) 0.10
With MS 807 (86.6) 120 (12.9) 5 (0.5)
APOA5 -12,238 T>C TT CT CC
Without MS 912 (41.3) 995 (45.1) 299 (13.5) 0.026
With MS 413 (44.3) 424 (45.5) 95 (10.2)
APOA4 Thr347Ser Thr347Thr Thr347Ser Ser347Ser
Without MS 1412 (64.0) 702 (31.8) 92 (4.2) 0.034
With MS 627 (67.3) 282 (30.3) 23 (2.5)
APOC3 -482 C>T CC CT TT
Without MS 1148 (52.0) 894 (40.5) 164 (7.4) 0.26
With MS 508 (54.5) 349 (37.4) 75 (8.0)
APOC3 3238 C>G CC CG GG
Without MS 1799 (81.5) 388 (17.6) 19 (0.86) 0.71
With MS 750 (80.5) 172 (18.4) 10 (1.1)
Values are number (%).
Table 6: Odds ratios for metabolic syndrome in carriers of the 
minor allele
SNP OR [95% CI] p
APOA5 Ser19Trp 1.30 [1.03–1.66] 0.03
APOA5 -12,238 T>C 0.81 [0.69–0.95] 0.01
APOA4 Thr347Ser 0.84 [0.70–0.99] 0.04
APOC3 -482 C>T 0.89 [0.76–1.06] 0.17
APOC3 3238 C>G 1.03 [0.84–1.26] 0.76
The reference groups were homozygous subjects for the frequent 
allele. Odds ratios and p values adjusted for age, gender and center.BMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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haplotype analyses with the two APOC3 SNPs did not
reveal any significant association with metabolic syn-
drome.
Discussion
The goal of the present study was to assess the contribu-
tion of SNPs in the APOA5/A4/C3/A1 cluster to the risk of
metabolic syndrome. Our results showed that the APOA5
Trp19 allele was associated with an increased risk of met-
abolic syndrome and that this association could possibly
be explained by an increase in plasma triglyceride levels.
Furthermore, the APOA5  -12,238C and APOA4  Ser347
alleles were associated with a lower risk of metabolic syn-
drome – possibly due to their negative linkage disequilib-
rium with the APOA5 Trp19 allele. In contrast, the APOC3
-482C>T and 3238C>G SNPs did not appear to be related
to metabolic syndrome in this French sample.
All 5 SNPs of the cluster tested in this study were associ-
ated with triglyceride levels. Compared with the most
common haplotype, haplotypes that carried either the
APOA5 Trp19 allele only or both the APOC3 -482T and
APOC3 3238G alleles were found to be independently
associated with elevated triglycerides. These results are
consistent with earlier studies in different population
samples that reported similar linkage disequilibrium pat-
terns and associations with triglycerides (driven by the
APOA5 Trp19 and APOC3 -482T alleles [20]). In addition
to elevated triglyceride levels, the APOA5  Trp19 and
APOA4 Thr347 alleles were associated with higher blood
pressure. A direct effect of APOA5 or APOA4 on blood
pressure regulation is unlikely. In contrast, there is exper-
imental evidence to suggest that chronic hypertriglyceri-
demia leads to endothelium dysfunction, which is
associated with an impaired response to vasodilator stim-
ulation [33] and a subsequent decrease in nitric oxide
availability [34] – phenomena which may result in
increased blood pressure.
The APOA5 Trp19 allele increased the odds ratio for met-
abolic syndrome, whereas the APOA5  -12,238C and
APOA4  Ser347 alleles decreased it. Other studies have
reported associations between APOA5  SNPs and meta-
bolic syndrome [8-12]. Our results extend this observa-
tion to a different European population sample. The
reduced risk of metabolic syndrome observed in carriers
of APOA5  -12,238C and APOA4  Ser347 alleles merely
reflected the negative linkage disequilibrium existing
between these alleles and the APOA5 Trp19 allele. Several
lines of evidence suggest that the association with meta-
bolic syndrome is mediated by triglycerides. Firstly, the
APOA5 Trp19 allele is associated strongly and independ-
ently with triglyceride levels but far less so with blood
pressure. Secondly, adjustment for triglycerides (but not
for other metabolic syndrome-related criteria) abolished
the associations between APOA5 or APOA4 SNPs and the
risk of metabolic syndrome. Overall, this suggests that
APOA5 and APOA4 genetic variability affected susceptibil-
ity to metabolic syndrome.
In contrast, the APOC3 -482C>T and APOC3 3238C>G
SNPs did not significantly affect the risk of metabolic syn-
drome in this sample of French origin, despite significant
association with triglyceride level. These SNPs do not
belong to the same haplotype as the APOA5 Ser19Trp SNP
and have an independent effect on plasma triglycerides,
which may explain the difference vis-à-vis APOA5. Fur-
thermore and in contrast to the APOA5 Ser19Trp SNP, the
APOC3 SNPs were not associated with another compo-
nent of metabolic syndrome (such as blood pressure)
which could explain this difference. Lastly, the prevalence
of hypertriglyceridemia was higher in carriers of the
APOA5 Trp19 allele (35%) than in carriers of the APOC3
-482T (23%) or APOC3 3238G (22%) alleles and thus
increased the probability of fulfilling the definition of
metabolic syndrome.
This study has both strengths and limitations. It was per-
formed on a representative sample of the French popula-
tion and therefore avoided potential selection bias for
patients and controls. There were more than 900 subjects
with metabolic syndrome, which yields enough statistical
power to detect an OR of 1.3 for an allele frequency of
10% at α = 0.05 and β = 90%. Despite this large number
of subjects with metabolic syndrome, the statistical power
of the study was still not sufficient to account for possible
type 1 error due to multiple testing. Therefore, corrections
for multiple testing were not applied in the present analy-
sis. In our sample, subjects without metabolic syndrome
were, on average, 5 years younger than those with meta-
bolic syndrome. Since metabolic syndrome prevalence
increases with age, this may possibly confound (underes-
timate) the odds ratio associated with the SNPs. However,
all our analyses were adjusted for age, in order to account
for a possible impact of the latter parameter on the associ-
ation. Since only a few SNPs per gene were studied, we
cannot completely rule out the possibility that other SNPs
in different gene loci or specific haplotypes can also con-
tribute to genetic susceptibility to metabolic syndrome.
Indeed, other studies have reported associations between
APOA5 SNPs and metabolic syndrome [8-12]. Lastly, we
used the NCEP working definition of metabolic syn-
drome; however, additional analyses using the IDF con-
sensus definition generated very similar conclusions and
suggested that choice of the definition of metabolic syn-
drome does not affect the relationship between metabolic
syndrome and the SNPs studied here.
Conclusion
Over the past decades, genetic variability in the APOA5/
A4/C3/A1 cluster has been associated (to varying extents)
with variability in plasma lipid, apolipoprotein and lipo-BMC Medical Genetics 2008, 9:84 http://www.biomedcentral.com/1471-2350/9/84
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protein levels and with an increased risk of cardiovascular
disease. The results of the present study further suggest
that the association of SNPs in this cluster with metabolic
syndrome may be explained by the propensity of plasma
triglycerides to increase in APOA5 Trp19 allele carriers.
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